Unlock expert insights for
complex cases with our
peer-to-peer advanced
reader training program
Images Courtesy of Dr. Gary Ulaner, Hoag Family Cancer Institute
GE HealthCare and DocPanel are collaborating to provide clinicians with peer-to-peer advanced reader training for
Cerianna, designed to enhance diagnostic confidence in complex cases.
How to access your peer-to-peer advanced reader training
1
Register
Complete the form below to enroll in the program
2
Account set-up
A DocPanel representative will connect with you within 48 hours to walk you through the process
3
Submit scans
Upload your Cerianna PET/CT scans securely through DocPanel’s platform
4
Learn from a specialist
Schedule a peer-to-peer consultation with a DocPanel nuclear medicine specialist to review findings
5
Apply insight
Use the expert feedback to support you in your clinical understanding
Why use Cerianna peer-to-peer advanced reader training with DocPanel?
Collaborate with confidence: Gain access to peer-to-peer education to discuss complex cases, helping with precise interpretations
Complimentary and convenient: This service is offered at no cost,
with flexible scheduling to fit your practice needs
Companies you can count on: GE HealthCare, a leader in molecular imaging, and DocPanel, a pioneer in radiology expertise, are committed to supporting clinicians in delivering personalized patient care
Register for peer-to-peer advanced reader training
*Disclaimer: Completion of Reader Training is required to access this program. GE HealthCare offers an option for reader training on the Cerianna
website. DocPanel does not provide medical advice, judgments, or diagnoses. Healthcare providers and their institutions are solely responsible for all
patient-related decisions, including image capture, interpretation, diagnosis, treatment, and management. Participation is limited to three program
sessions per healthcare provider.
About GE HealthCare and DocPanel
GE HealthCare is a global leader
in medical technology and
pharmaceutical diagnostics,
advancing precision care through innovations like
Cerianna, the only FDA-approved imaging agent
reflecting the binding ability of estradiol to the
estrogen receptor in recurrent or metastatic breast
cancer lesions.
DocPanel is a premier network of board-certified radiologists and nuclear medicine specialists, providing expert diagnostic support to healthcare professionals worldwide.
Together, we’re empowering clinicians to deliver exceptional patient outcomes.
About Cerianna
Cerianna reflects the potential binding ability of estradiol to the estrogen receptor, offering high diagnostic accuracy to detect ER-positive lesions in recurrent or metastatic breast cancer.
IMPORTANT SAFETY INFORMATION
INDICATIONS AND USAGE
CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
In clinical trials evaluating the safety of CERIANNA in patients with breast cancer (n=1207), the following adverse reactions occurred at a rate < 1%: injection-site pain and dysgeusia.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch.
For full Prescribing Information, click here.
GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe
500 W. Monroe Street | Chicago, IL 60661
© 2026 GE HealthCare
Cerianna is a trademark of GE HealthCare
GE is a trademark of General Electric Company used under trademark license.
January 2026 | JB11837US